Study Highlights Genetic Influence on CAR-T Therapy Efficacy and Safety
A recent study published in Science Immunology has revealed that inherited genetic variants can significantly impact the efficacy and safety of CAR-T cell therapy. Researchers analyzed whole-genome sequencing data from over 200 patients with aggressive lymphoma who were treated with axicabtagene ciloleucel in the ZUMA-1 and ZUMA-7 trials. The study found that certain genetic variants, such as PTPN22, were associated with greater CAR-T cell expansion, while ADAMTSL3 variants were linked to reduced treatment-related toxicity. These findings suggest that a patient's inherited genome can influence the biological characteristics of the CAR-T product, potentially leading to improved patient risk stratification, toxicity monitoring, and CAR-T engineering. 
